Thiogenesis Therapeutics Corp (TTI) Noticias

$TTI.v showing some strong signals. Lets see if it can hold going into European patient dosing$TTI $TTIPF pic.twitter.com/N12sWugqTk— Airic (@airic101) March 26, 2025

Last month, Thiogenesis (TTI.v TTIPF) received final EU clearance to begin a Phase 2 trial of its lead drug for MELAS, a rare mitochondrial disease. The drug targets oxidative stress and amino acid deficiencies and is also in development for Leigh syndrome (1 in 40,000 births) and pediatric MASH. Full news⬇️
https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/67b0bfe1bbff5977b54dadd6_TTI-NR%20250127%20MELAS%20CTA%20Clearance%20Final.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

Targeting MELAS, Leigh Syndrome & pediatric MASH, three high-need conditions with no approved treatments, Thiogenesis Therapeutics (TTI.v | TTIPF) is advancing their lead drug, TTI-0102 which offers 24-hour sustained delivery of cysteamine and is eligible for a streamlined FDA pathway.
• 2025 Phase II Trials
• 3 rare pediatric/metabolic diseases
• New EU patent protection through 2037
• Potential blockbuster in a multi-billion dollar market

Learn more about this opportunity here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

What if a single compound could unlock a new wave of treatments for rare pediatric diseases by targeting the root cause, mitochondrial dysfunction?
 
Thiogenesis Therapeutics (TTI.v TTIPF) is taking aim with TTI-0102, a next-gen cysteamine prodrug that’s showing promise in MELAS, Leigh Syndrome, and Pediatric MASH—without the dose-limiting side effects that held earlier drugs back. Moving toward key clinical milestones that could reshape mitochondrial medicine, TTI is gearing up for Phase II trials in 2025 for its next-gen mitochondrial therapy: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

2025 Phase II Trials for Groundbreaking Mitochondrial Therapy - Moving toward key clinical milestones that could reshape mitochondrial medicine, Thiogenesis Therapeutics (TTI.v TTIPF)  is advancing TTI-0102, a next-generation cysteamine prodrug designed for severe conditions with no approved treatments. More details here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/ 

Breakthrough Drug for Rare Diseases? Thiogenesis Therapeutics (TTI.v TTIPF) is gearing up for Phase II trials in 2025 for its next-gen mitochondrial therapy, targeting MELAS, Leigh Syndrome, and Pediatric MASH—all severe diseases with no approved treatments.
 
With a streamlined FDA pathway, 24-hour sustained release technology, and new patent protection in Europe until 2037, this could be a development in the industry.
 
Full DD & latest updates here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

As the global demand for innovative treatments targeting oxidative stress-related diseases continues to rise, Thiogenesis Therapeutics (TTI.V TTIPF) is pioneering a breakthrough approach with its next-generation thiol-based therapeutics.

Focused on tackling unmet medical needs and rare metabolic disorders TTI's lead drug is advancing in Phase II Trials, positioning the company at the forefront of a rapidly expanding biotech sector andoffering investors a compelling opportunity in the future of precision medicine. More info here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Pioneering a new generation of thiol-based therapeutics, Thiogenesis Therapeutics (TTI.V TTIPF)is addressing long-standing challenges that have hindered broader applications of these potent compounds and targeting a substantial growing market.

At the forefront of this innovation is TTI-0102, an asymmetric disulfide prodrug designed to overcome the side effects, short half-life, and dosing limitations traditionally associated with thiol-active drugs.

Set to complete Phase 2 trials this year, TTI represents a rare opportunity in the pharmaceutical space: a company advancing a clinically validated, next-generation prodrug with broad therapeutic potential, improved safety, and a streamlined regulatory path. More info here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Mitochondrial and metabolic diseases often have limited treatment options, however, Thiogenesis Therapeutics (TTI.V TTIPF) is working to change that with its next-generation prodrug, TTI-0102, designed to combat oxidative stress by enhancing intracellular glutathione production.
 
Advancing a promising pipeline targeting MELAS, Leigh Syndrome, and Pediatric NASH/MASH—each with multi-billion-dollar market potential, TTI is leveraging a cost-efficient regulatory strategy, positioning the company for multiple Phase 2 trials in 2025. Learn more about this innovative biotech and its transformative approach to mitochondrial medicine here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Leading the way in mitochondrial medicine, Thiogenesis Therapeutics (TTI.v TTIPF) is developing cysteamine-based therapies targeting oxidative stress which face significant unmet medical needs as a key factor in MELAS, Leigh Syndrome, and Pediatric NASH/MASH

With Phase 2 clinical trials set for 2025, a cost-efficient regulatory pathway, and a multi-billion-dollar market potential, TTI is positioned for transformational growth in advancing toward key value-driving milestones that could reshape the treatment landscape for these debilitating diseases. Learn more about this high-potential biotech opportunity here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Rare and metabolic diseases remain some of the most pressing unmet medical challenges, and Thiogenesis Therapeutics (TTI.v TTIPF) is at the forefront of innovation with its next-generation cysteamine-based therapy targeting oxidative stress, an underlying driver of MELAS, Leigh Syndrome, and Pediatric NASH/MASH.

With Phase 2 clinical trials set for 2025, a cost-efficient regulatory pathway, and multi-billion-dollar market potential, Thiogenesis is rapidly progressing toward breakthroughs in mitochondrial medicine. Supported by a seasoned leadership team and strong financial positioning, the company is on the brink of value-driving milestones that could reshape the treatment landscape for these debilitating conditions.

Discover more about this biotech opportunity here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Pioneering next-generation cysteamine-based therapeutics to combat oxidative stress-driven diseases, Thiogenesis Therapeutics (TTI.v TTIPF) is focuses on rare pediatric conditions that have little or no treatments.
 
As its lead drug, TTI-0102, advances toward multiple Phase 2 trials in 2025, TTI is leveraging a cost-efficient regulatory strategy to accelerate development in multi-billion-dollar markets like MELAS, Leigh Syndrome, and Pediatric NASH/MASH—making it a compelling opportunity in mitochondrial medicine. More Info: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Backed by expanding patent protection and a growing clinical pipeline, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing its lead drug, TTI-0102, into Phase II clinical trials in 2025, targeting rare and severe mitochondrial diseases with no approved treatments. With a unique sustained-release approach and a streamlined regulatory pathway, the company is positioning itself to address significant unmet medical needs in MELAS, Leigh syndrome, and pediatric MASH.

For more information, refer to this deep dive DD: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

As rare and metabolic diseases continue to present major unmet medical needs, Thiogenesis Therapeutics (TTI.V TTIPF) is pioneering a next-generation cysteamine-based therapy to combat oxidative stress—an underlying driver of MELAS, Leigh Syndrome, and Pediatric NASH/MASH. With Phase 2 clinical trials set for 2025, a cost-efficient regulatory pathway, and multi-billion-dollar market potential, Thiogenesis is rapidly advancing toward transformative breakthroughs in mitochondrial medicine. Backed by an experienced leadership team and strong financial positioning, the company is on the verge of major value-driving milestones. Read more about this high-growth biotech opportunity here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/  

Targeting a large market opportunity in rare and metabolic diseases, Thiogenesis Therapeutics (TTI.V TTIPF) is developing breakthrough treatments for severe pediatric conditions with few existing options: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/ 
 
Set to advance into Phase 2 studies this year, TTI's lead drug, TTI-0102, targets mitochondrial and metabolic disorders, addressing high-unmet medical needs. Utilizing a faster, cost-effective approval pathway, TTI aims to bring treatments to patients as quickly as possible.
 

Thiogenesis Therapeutics (TTI.V TTIPF) is a biotech company developing new treatments for serious pediatric diseases that have few options. Their lead drug, TTI-0102, is designed to help mitochondrial and metabolic disorders which have large market potential. After showing it can be safely used in Phase 1 trials, the drug is now moving into Phase 2 studies in 2025, targeting conditions like MELAS, Leigh Syndrome, and Pediatric NASH/MASH: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Using a faster and more cost-effective approval process, Thiogenesis is working to bring its treatments to patients as soon as possible. The company is backed by an experienced team and top scientists, helping guide its research and development. With strong financial backing and key milestones ahead, Thiogenesis is well-positioned to make a real impact in rare and metabolic disease treatment.

Thiogenesis Therapeutics (TTI.V TTIPF) is a clinical-stage biotechnology company focused on developing novel cysteamine-based therapeutics for pediatric diseases with significant unmet medical needs: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

The company’s lead compound, TTI-0102, is a next-generation prodrug designed to enhance intracellular glutathione production, addressing oxidative stress—a key driver of mitochondrial and metabolic diseases. Backed by an experienced leadership team and scientific advisors from leading institutions, the company is strategically advancing its mission to deliver transformative therapies in rare and metabolic diseases.

Thiogenesis Therapeutics (TTI.V TTIPF) is pioneering a next-generation cysteamine prodrug, designed to overcome the limitations of traditional treatments for mitochondrial and metabolic diseases. With demonstrated safety in Phase 1 trials, their lead candidate, TTI-0102, is positioned as a best-in-class therapy targeting oxidative stress—a key driver of diseases like MELAS and Leigh Syndrome: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

By leveraging an efficient regulatory pathway (505(b)(2)) and small confirmatory human efficacy trials, TTI is advancing toward Phase 2 trials in 2025 with a multi-billion-dollar market opportunity.

Focused on developing innovative treatments for pediatric diseases with significant unmet needs, Thiogenesis Therapeutics (TTI.V TTIPF) has developed a next-generation cysteamine prodrug designed to overcome the limitations of traditional cysteamine-based therapies, TTI-0102: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/
 
 With demonstrated safety in Phase 1 human trials, TTI-0102 has the potential to be a best-in-class therapy for combating oxidative stress, a key driver in mitochondrial and metabolic diseases. By leveraging a cost- and time-efficient development model, including the 505(b)(2) regulatory pathway and small confirmatory human efficacy trials, TTI is advancing a promising therapeutic approach with multi-billion-dollar market potential with Phase 2 trials set to initiate in 2025 for MELAS and Leigh Syndrome.

Pioneering the development of novel thiol-based compounds with potent antioxidant and anti-inflammatory properties, Thiogenesis Therapeutics (TTI.V TTIPF) is targeting mitochondrial dysfunction, a key factor in various inherited and acquired diseases, including metabolic disorders like type 2 diabetes and fatty liver disease: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

The company's lead compound, TTI-0102, has demonstrated high-dose tolerability in Phase 1 studies and is advancing into Phase 2 trials for conditions such as MELAS, Leigh syndrome, and pediatric MASLD/MASH. With a robust pipeline, experienced leadership, and strategic initiatives to increase market presence, TTI is well-positioned to address significant unmet medical needs in mitochondrial and metabolic diseases.

Set to launch Phase II trials in 2025 for its lead compound, TTI-0102, Thiogenesis Therapeutics (TTI.V TTIPF) is addressing significant unmet medical needs starting with MELAS, a Condition with few or no approved treatments. As a prodrug of cysteamine, TTI-0102 enhances mitochondrial function by boosting glutathione levels, offering a sustained 24-hour release for improved tolerability and bioavailability: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/ 

Advancing next-generation mitochondrial disease therapies, Thiogenesis Therapeutics (TTI.V TTIPF) is a clinical-stage biopharmaceutical company, set to launch Phase II trials in 2025 for its lead compound, TTI-0102, a next-generation thiol-active therapeutic targeting MELAS, Leigh syndrome, and pediatric MASH, all conditions with few or no approved treatments: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/
 
Unlike traditional cysteamine-based therapies, TTI-0102 offers sustained 24-hour release, improving both tolerability and bioavailability while leveraging the FDA’s 505(b)(2) regulatory pathway for a potentially accelerated approval process. With expanding patents, a streamlined regulatory path, and a focus on high-need mitochondrial diseases, Thiogenesis is advancing toward key milestones that could transform treatment options in this critical space.
 

Clinical-stage biopharmaceutical company developing thiol-active therapeutics for mitochondrial diseases, Thiogenesis Therapeutics (TTI.V TTIPF), is preparing to launch Phase II clinical trials in 2025 for its lead compound, TTI-0102: TODAY: @thiogenesis Increases Investor Visibility Ahead of Phase 2 Clinical Trials in Europe$TTI.V $TTIPF

Ahead of commencing its Phase 2 clinical trial in Europe, $TTI entered into a consulting and investor relations agreement with a digital stock market news portal to… https://t.co/EKWlN7radC pic.twitter.com/XfWopUUQiU— Stock Master Flash (@StckMasterFlash) February 20, 2025

Designed to address significant unmet medical needs, TTI-0102 is being developed for MELAS, Leigh syndrome, and pediatric MASH, all of which have limited or no approved treatments, highlighting the urgent demand for innovative treatment options.

TTI-0102 is a prodrug that metabolizes into cysteamine, a key precursor to glutathione, an essential mitochondrial antioxidant that combats oxidative stress and mitochondrial dysfunction.

Thiogenesis Therapeutics (TTI.V TTIPF) is gaining momentum as it prepares for its Phase 2 clinical trial in Europe, expanding investor awareness through a new agreement with a Germany-based digital stock market news portal. This strategic move enhances TTI’s visibility, broadens its shareholder base, and strengthens its European network—critical as the company targets a multi-billion-dollar market with its lead candidate, TTI-0102: TODAY: @thiogenesis Increases Investor Visibility Ahead of Phase 2 Clinical Trials in Europe$TTI.V $TTIPF

Ahead of commencing its Phase 2 clinical trial in Europe, $TTI entered into a consulting and investor relations agreement with a digital stock market news portal to… https://t.co/EKWlN7radC pic.twitter.com/XfWopUUQiU— Stock Master Flash (@StckMasterFlash) February 20, 2025
 
With a Phase 2 trial set to assess TTI-0102 for MELAS, a severe and currently untreatable metabolic disorder, the company is well-positioned for long-term growth. Beyond MELAS, TTI has the potential to expand into other high-impact diseases like Leigh’s syndrome, Rett syndrome, and pediatric MASH. With regulatory clearance secured and a de-risked development path ahead, greater investor attention supports Thiogenesis’ ability to accelerate clinical progress and unlock significant value.

Ahead of commencing its Phase 2 clinical trial in Europe, Thiogenesis Therapeutics (TTI.V TTIPF) entered into a consulting and investor relations agreement a Germany-based digital stock market news portal to analyze and assess opportunities to broaden the company's shareholder base and expand its contact network within Europe: https://www.newsfilecorp.com/release/241481/Thiogenesis-Announces-European-Consulting-and-Investor-Relations-Agreement

Notably, TTI is targeting a multi-billion-dollar market opportunity with its lead candidate, TTI-0102, in holding a multi-country, multi-center, randomized, double-blind, placebo-controlled study in France and the Netherlands: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Having received the final regulatory clearance for its Phase 2 clinical trial in Europe, Thiogenesis Therapeutics (TTI.V TTIPF) is targeting a multi-billion-dollar market opportunity with its lead candicate, TTI-0102: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/ 
 
The multi-country, multi-center, randomized, double-blind, placebo-controlled study will be held in France and the Netherlands to assess the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a severe and currently untreatable disorder affecting energy metabolism at the cellular level.
 

Advancing Next-Gen Mitochondrial Disorder Treatments - As a clinical-stage biotechnology company, Thiogenesis Therapeutics is pioneering thiol-based therapeutics to combat oxidative stress and mitochondrial dysfunction—key drivers of devastating diseases: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Its lead candidate, TTI-0102, is currently in a Phase 2 clinical trial in Europe for MELAS, a severe, currently untreatable disorder affecting energy metabolism at the cellular level. With a differentiated platform and a multi-billion-dollar market opportunity, TTI is strategically positioned to expand beyond MELAS into additional high-impact indications, including Leigh’s syndrome, Rett syndrome, and pediatric MASH—diseases with significant unmet medical needs.

NEW OTCQX BEST MARKET LISTING - Thiogenesis Therapeutics (TTI.v TTIPF: TODAY: @thiogenesis $TTI.v commenced trading on the OTCQX Best Market in the US under the symbol $TTIPF

The clinical-stage biotechnology company recently received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for MELAS, a rare inherited disorder with… https://t.co/ZLzwpHl7R7 pic.twitter.com/7sXsFotgjP— Stock Master Flash (@StckMasterFlash) February 12, 2025

As a clinical-stage biotechnology company targeting mitochondrial disorders, TTI is advancing its lead candidate with a Phase 2 clinical trial in Europe for MELAS—a devastating condition with no approved treatments. With a differentiated approach leveraging thiol-based therapeutics to address oxidative stress and mitochondrial dysfunction, Thiogenesis is tapping into a multi-billion-dollar market opportunity.

Beyond MELAS, its proprietary platform has broader potential in neurodegenerative and metabolic diseases, including Leigh’s syndrome, Rett syndrome, and pediatric MASH, offering a pipeline with significant upside. With final regulatory clearance secured and a derisked development path ahead, TTI presents a compelling biotech growth story.

Enhancing access and visibility for U.S. investors, Thiogenesis Therapeutics (TTI.v TTIPF) has commenced trading on the OTCQX Best Market under the ticker symbol TTIPF: TODAY: @thiogenesis $TTI.v commenced trading on the OTCQX Best Market in the US under the symbol $TTIPF

The clinical-stage biotechnology company recently received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for MELAS, a rare inherited disorder with… https://t.co/ZLzwpHl7R7 pic.twitter.com/7sXsFotgjP— Stock Master Flash (@StckMasterFlash) February 12, 2025

With a multi-billion-dollar market opportunity, this follows the clinical-stage biotechnology company receiving final regulatory clearance - a major mitigation of risk - to launch a Phase 2 clinical trial in Europe for MELAS, a severe mitochondrial disorder with no approved treatments.

Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF, increasing visibility for U.S. investors: https://www.newsfilecorp.com/release/240489/Thiogenesis-Announces-Commencement-of-OTCQX-Trading-in-the-U.S

Targeting multi-billion-dollar market potential, the clinical-stage biotechnology company recent received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS), a rare inherited mitochondrial disorder with no approved treatments: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

With strong regulatory positioning, expanding patent coverage, and a multi-billion-dollar market potential, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing into Phase II clinical trials for its lead drug TTI-0102 as a potential treatment for MELAS: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

TTI-0102, leverages sustained-release cysteamine to enhance mitochondrial function and combat oxidative stress and is poised to be a breakthrough treatment not only for MELAS but additionally for Leigh syndrome, and pediatric MASH— all devastating diseases with no approved therapies and urgent unmet medical needs.

Thiogenesis Therapeutics (TTI.v TTIPF) is gearing up for Phase II clinical trials in 2025 with a cutting-edge treatment targeting MELAS, Leigh syndrome, and pediatric MASH—all diseases with no approved treatments and massive unmet medical needs.

Their lead drug, TTI-0102, delivers sustained-release cysteamine, a key player in mitochondrial health and oxidative stress reduction. With regulatory advantages, expanding patent protection, and a billion-dollar market potential, is this an overlooked opportunity? Full DD & latest progress here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Set to begin shortly, Thiogenesis Therapeutics (TTI.v) will be commencing a multi-country, multi-center trial in France and the Netherlands to evaluate the safety, tolerability, and efficacy of its TTI-0102 as a potential treatment for MELAS, a rare mitochondrial disorder with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to proceed with its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

The multi-country, multi-center trial in France and the Netherlands will evaluate the safety, tolerability, and efficacy of oral TTI-0102 in 12 patients over six months, with an interim analysis at three months.

Notably, TTI-0102 is a prodrug designed to increase intracellular glutathione and taurine, addressing key deficiencies in MELAS patients. It improves on earlier thiol-based treatments by offering a longer half-life and fewer side effects. MELAS, a rare mitochondrial disorder affecting 4.4 per 100,000 people, leads to seizures, fatigue, and muscle weakness, with oxidative stress and taurine deficiency as potential treatment targets.

Gearing up for Phase II clinical trials in 2025 for TTI-0102, a next-generation treatment targeting MELAS, Leigh syndrome, and pediatric MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is a unique clinical-stage biotech company focused on devastating diseases with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

With its innovative sustained-release cysteamine prodrug, streamlined FDA approval pathway, and expanding global patents, Thiogenesis is rapidly advancing toward potentially game-changing treatments for mitochondrial and metabolic disorders.

Allowing the company to proceed with its multi-center trial in France and the Netherlands, evaluating the safety, tolerability, and efficacy of TTI-0102 in 12 patients over six months, Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to initiate its Phase 2 clinical trial: Today, @thiogenesis announced it received the final EU clearance of CTA to initiate Phase 2 Clinical Trial in MELAS $TTI.v #biotech

➡️Testing TTI-0102 as a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS).

➡️Trial is… https://t.co/5yZTNh6zEF— Stock Master Flash (@StckMasterFlash) January 27, 2025

With no approved treatments for MELAS, TTI-0102 offers a novel approach by boosting intracellular glutathione and taurine, addressing key deficiencies in patients. CEO Patrice Rioux highlighted its potential as a viable therapeutic, overcoming limitations of earlier thiol-based drugs. This approval marks a significant step in advancing a promising treatment for an unmet medical need.

Thiogenesis Therapeutics (TTI.v TTIPF) is working to launch Phase II trials in 2025 for TTI-0102, a drug targeting MELAS, Leigh syndrome, and pediatric MASH, all with significant unmet medical needs. TTI-0102 offers sustained release unlike other cysteamine-based treatments, reducing oxidative stress while improving tolerability and bioavailability. More here: https://thiogenesis.webflow.io/investors

*Posted on behalf of Thiogenesis Therapeutics Corp.

Marking a significant mitigation of risk, Thiogenesis Therapeutics (TTI.v) has received EU clearance to commence its Phase 2 clinical trials for TTI-0102 as a potential treatment for MELAS: Today, @thiogenesis announced it received the final EU clearance of CTA to initiate Phase 2 Clinical Trial in MELAS $TTI.v #biotech

➡️Testing TTI-0102 as a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS).

➡️Trial is… https://t.co/5yZTNh6zEF— Stock Master Flash (@StckMasterFlash) January 27, 2025
 
Set to begin shortly, the trials are a multi-country, multi-center, randomized, double-blind, placebo-controlled study which will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.

With the acceptance of the final regulatory clearance from the European Medicines Agency needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for MELAS, Thiogenesis Therapeutics (TTI.v) is set to begin shortly: Today, @thiogenesis announced it received the final EU clearance of CTA to initiate Phase 2 Clinical Trial in MELAS $TTI.v #biotech

➡️Testing TTI-0102 as a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS).

➡️Trial is… https://t.co/5yZTNh6zEF— Stock Master Flash (@StckMasterFlash) January 27, 2025

The multi-country, multi-center, randomized, double-blind, placebo-controlled study will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.

Today, Thiogenesis Therapeutics (TTI.v) announced that the European Medicines Agency (EMA) has accepted the final regulatory clearance (CTA Part II) needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.newsfilecorp.com/release/238463/Thiogenesis-Receives-Final-EU-Clearance-of-CTA-to-Initiate-its-Phase-2-Clinical-Trial-in-MELAS

The trial is set to begin shortly, following the activation of clinical trial sites, multi-country, multi-center, randomized, double-blind, placebo-controlled study in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS. Notably, there are currently no approved drugs for the condition.

Thiogenesis Therapeutics (TTI.v) is a groundbreaking clinical-stage biotech company revolutionizing the treatment of rare mitochondrial dysfunction diseases through its innovative thiol-active compounds: A High-Growth Biotech Opportunity - @thiogenesis $TTI.v is a clinical-stage biotech company specializing in thiol-active compounds to treat mitochondrial dysfunction diseases.

Its lead product, TTI-0102, is a prodrug of cysteamine designed to improve dosing and reduce side… pic.twitter.com/lB2rgtcZaD— Stock Master Flash (@StckMasterFlash) January 23, 2025

Its flagship product, TTI-0102, is a prodrug of cysteamine designed to enhance dosing efficiency and minimize side effects that's focused on high-value, rare conditions in a lucrative CAD 9.8 billion global market opportunity.

Advancing its ambitious pipeline with clinical trials for TTI-0102, TTI is set to tackle multiple rare diseases with key milestones including Phase II trials for MELAS and Leigh Syndrome beginning in 2025, with market launches anticipated by 2026-2027 and projected combined peak sales of CAD 4.14 billion.

Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company specializing in thiol-active compounds to treat mitochondrial dysfunction diseases. Its lead product, TTI-0102, is a prodrug of cysteamine designed to improve dosing and reduce side effects and, according to Valuation Lab, with a risk-adjusted net present value (NPV) of CAD 7.5 per share, Thiogenesis offers a significant upside of 1130%: 'A Prodrug for Mito-Dysfunction' Offering 1130% Upside Potential - @thiogenesis Research Report Summary $TTI.v

Clinical-stage #biotech company TTI is advancing its lead product, TTI-0102, to treat rare mitochondrial diseases, including MELAS and Leigh Syndrome (LS).

⭐️Company… https://t.co/5yZTNh6zEF pic.twitter.com/u3doqcjzH3— Stock Master Flash (@StckMasterFlash) December 24, 2024

Targeting three rare diseases and conditions with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is represents a significant opportunity in addressing both rare diseases and broader oxidative stress-related challenges with its innovative thiol-based drug TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Streamlining development by leveraging expedited regulatory pathways in the US and Europe, TTI is able to significantly reduce costs and time to market in an estimated $9.8 billion market opportunity, strongly positioning the company to address critical gaps in the rare disease and antioxidant therapy space.

Clinical stage biotech company Thiogenesis Therapeutics (TTI.v) and its lead product, innovative thiol-based drug TTI-0102, have significant potential, extending beyond addressing rare conditions—it signifies a broader opportunity to revolutionize therapeutic strategies for oxidative stress-related diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

For MELAS, affecting 30,000 individuals in the US, TTI-0102’s ability to mitigate neurological symptoms and stroke-like episodes through mitochondrial support is groundbreaking. In Rett Syndrome, the drug’s promotion of Brain-Derived Neurotrophic Factor (BDNF) could restore nerve cell health and improve motor and cognitive function. Similarly, in pediatric NASH, which impacts 7 million children in the US, TTI-0102’s anti-inflammatory and antioxidant properties offer hope for a condition leading to severe liver complications. With a strong safety profile derived from cysteamine’s pediatric use and a focus on conditions with no existing approved treatments, TTI represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.

Poised to transform the treatment landscape for rare diseases and conditions with significant unmet medical needs through its innovative thiol-based drug, TTI-0102, Thiogenesis Therapeutics (TTI.v) offers a novel approach to conditions such as MELAS, Rett Syndrome, and pediatric NASH in targeting mitochondrial dysfunction to address the root causes of these diseases, which currently lack approved therapies: Key Mechanisms for @thiogenesis Lead Product Targeting Unmet Medical Needs $TTI.v

Capitalizing on a $9.8B opportunity in the global rare disease & antioxidant therapies space, $TTI is targeting unmet medical needs including rare conditions with its lead product TTI-0102.… https://t.co/BJjNB4zm3z— Stock Master Flash (@StckMasterFlash) January 17, 2025

Leveraging expedited regulatory pathways in the US and Europe, TTI can streamline development by referencing existing safety data from similar compounds, significantly reducing costs and time to market. With an estimated $9.8 billion market opportunity, TTI is well-positioned to address critical gaps in the rare disease and antioxidant therapy space and represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.

Capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space, Thiogenesis Therapeutics (TTI.v) is focused on the development of thiol-based drugs with its lead product TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/    

TTI-0102 leverages its proven safety profile (from cysteamine's pediatric use) to target critical unmet medical needs in MELAS, Rett Syndrome, and NASH. By addressing mitochondrial dysfunction through innovative mechanisms, Thiogenesis presents a promising therapeutic approach for these challenging conditions.

Thiogenesis Therapeutics (TTI.v) is capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space by focusing on the development of thiol-based drugs. Leveraging unique properties to address oxidative stress and mitochondrial dysfunction, TTI's novel lead product offers targeted solutions for unmet medical needs including rare conditions such as MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH : https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Benefitting from strong regulatory incentives for orphan drug development, TTI's lead product strategically targets both niche and broader applications, positioning the company to drive innovation and deliver significant value in a competitive and high-potential therapeutic area.

Addressing oxidative stress and mitochondrial dysfunction, a $9.8B market with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a rising player in the biotech sector with its novel lead product, TTI-0102, a prodrug of cysteamine designed to improve dosing and reduce side effects: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

By pioneering a platform centered on thiol-based molecules, Thiogenesis aims to deliver groundbreaking therapies for rare disorders and conditions lacking effective treatments. Adding to their appeal, orphan disease therapies often benefit from faster regulatory approval, lower R&D expenditures, and extended periods of market exclusivity.

Emerging biopharmaceutical company, Thiogenesis Therapeutics (TTI.v), is focused on harnessing the therapeutic potential of sulfur-based compounds to address oxidative stress and mitochondrial dysfunction, both of which are implicated in a wide range of diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

With an innovative platform leveraging the unique properties of thiol-based molecules, TTI's core focus is on developing novel treatments for orphan diseases and conditions with significant unmet medical needs, targeting a CAD$9.8B market opportunity. Notably, this focus on orphan diseases offers the potential for expedited regulatory pathways, reduced development costs, and attractive market exclusivity periods.

Targeting a projected global market opportunity of CAD$9.8B, Thiogenesis Therapeutics (TTI.v) is focused on addressing rare conditions including MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH with its lead product, TTI-0102. Poised to make a significant impact on the market, TTI is at the start of a transformational year with multiple trials and regulatory filings expected to provide significant inflection points: Unlocking Rare Disease Potential: Why @thiogenesis Could Be a Game-Changer $TTI.v

Interested in a unique opportunity in the #biotech space?

Check out $TTI, a clinical-stage company specializing in compounds treating rare mitochondrial dysfunction diseases, an estimated global… https://t.co/dCTAwEohCf pic.twitter.com/0UtyUyaYWb— Stock Master Flash (@StckMasterFlash) January 10, 2025

Interested in a unique opportunity in biotech space? Check out Thiogenesis Therapeutics (TTI.v), a clinical-stage company specializing in thiol-active compounds to treat rare mitochondrial dysfunction diseases, targeting an estimated global market of CAD 9.8 billion:  'A Prodrug for Mito-Dysfunction' Offering 1130% Upside Potential - @thiogenesis Research Report Summary $TTI.v

Clinical-stage #biotech company TTI is advancing its lead product, TTI-0102, to treat rare mitochondrial diseases, including MELAS and Leigh Syndrome (LS).

⭐️Company… https://t.co/5yZTNh6zEF pic.twitter.com/u3doqcjzH3— Stock Master Flash (@StckMasterFlash) December 24, 2024

With its lead product, TTI-0102—a prodrug of cysteamine designed to improve dosing and reduce side effects—Thiogenesis is poised to make a significant impact in treating conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH. Notably, Valuation Lab estimates a risk-adjusted net present value of CAD 7.5 per share, translating to a staggering 1130% upside.